Analytical Data
-
基因名
LCN4
- Application
-
别名
VNSP2; Vomeronasal secretory protein II
-
种属
Mouse
-
表达系统
E. coli
-
标签
N- His & GST
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q62472
-
表达区间
Tyr20~Ser178
-
分子量
48kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The LCN4 (lipocalin 4) protein, also known as the fetal antigen-1, is a member of the lipocalin family, which is characterized by a common structural motif of an 8-stranded β-barrel. LCN4 has garnered attention due to its significant roles in various physiological and pathological processes, including adipogenesis, cellular signaling, and potential involvement in reproductive functions. Research indicates that LCN4 may act as a biomarker for certain types of cancer, particularly in breast and prostate tissues, and it is implicated in metabolic disorders and obesity-related conditions. The recombination and expression of LCN4 as a fusion protein have opened new avenues for studying its functional roles at the molecular level, allowing researchers to investigate its interactions with other proteins and its effects on cellular behaviors. Furthermore, understanding the structure-function relationship of LCN4 through recombinant technology can aid in developing therapeutic strategies that target its pathways, thus holding promise for clinical applications in oncology and metabolic disease management. As research in this area progresses, LCN4 may emerge as a vital target for drug development and diagnostic applications, underscoring the importance of detailed studies on this intriguing lipocalin.
